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Quality Assurance of Medical Evidence 
Brief Outline 
 Reflections on the past  
 Previous  home and institution 
 Path to a clinical academic career in pathology 
 Role of a pathologist in diagnostic medicine 
 Cancer biomarking 
 Role in diagnostic pathology 
 Quality assurance 
 Conclusion & Discussion 
 
Career Path in  
Clinical Academic Pathology 
 2nd MB   
 Glasgow University, Scotland  2 years 
 BSc (Hons) Biochemistry   
 Glasgow University, Scotland  2 years  
 PhD in Immunology     
 Birmingham University, England  3 years 
 MBChB      
 Birmingham University, England  4 years 
 MRCPath      
 Cardiff University, Wales    12 years 
 
Role of Pathology in Diagnostic Medicine 
 Represent several different specialties 
 Cellular pathology, haematology, medical biochemistry & 
microbiology, clinical immunology   
 Pathologists work in laboratories, in clinics and wards   
 Millions of pathology tests /year 
  14 tests for every man, woman and child in UK per year 
 Many major advances  depend on pathologists 
 Guidance to treatment of cancer & genetic disorders  
 ensuring safe blood transfusions 
 developing vaccines against infectious diseases   
 Pathology is involved in 70% of all diagnoses and majority of 
the scientific advances made in Medicine 
 
Role of a Pathologist in Cancer Medicine 
Diagnostic, prognostic & predictive analysis 
of disease as a guide for more precise & 
effective patient management  
Translational Research  
Quality assurance  
 Breast cancer as an example 
 
Tissue Based Analysis of Cancer  
 Core & excision biopsies 
 Macroscopic examination 
 Microscopic examination 
 Molecular analysis 
 Immunohistochemistry 
 In situ hybridisation 
 Genomic analysis 
 
 
Breast Cancer Biomarking  
Workload: U.K. and Wales 
 
• UK  
• 50,000 new cases / year 
• Wales  
• 2,500 new cases/year 
• South East Wales Cancer 
Network 
• 1,500 new cases/year 
 
 
 
 
Symptomatic  Diagnosis 
Clinical  Diagnosis – Physical Examination 
 Clinical         Radiological    Pathological 
                         
• Mammogram  - FNAC 
                        -  
• U/S   - Core bx 
                         
• MRI scan   - Excision bx 
 
Triple Assessment Confirmation 





Breast Cancer Diagnostic Process 
Patient  
Tissue 
Preparation  
Microscopy/  
Interpretation  
Biopsy   
MDT 
Special 
Techniques 
Molecular 
pathology  
Biopsy Processing & Analysis   
Macroscopic examination 
Microscopic examination 
Immunocytochemistry 
Molecular analysis 
Benign lesion 
Malignant lesion 
  
Prognostic Typing of Breast Cancer 
Histopathology Minimum Data Set, UK 
 Excision margins 
 Tumour size 
 Histological type 
 Histological grade 
 Lymph node stage 
 Vascular invasion 
 In situ component 
 Hormone receptor status 
 HER2 Status 

Nottingham Tenovus Primary Breast Cancer 
Study 
Tumour Size 
2 cm or less 
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Histological Grade 
Grade 1 
 
 
Grade 2 
Grade 3 
0
. 2
. 4
. 6
. 8
1
C
u
m
.
 
S
u
r
v
i
v
a
l
0 4 8 9 6 1 4 4 1 9 2 2 4 0 2 8 8
T i m e
2 4 6 . 7 2 3 2 < . 0 0 0 1
Ch i - Sq u a r eDF P- Va l u e
  712  342  76 Grade 1 
1289   403  82 Grade 2 
1717  414  96 Grade 3
    
0 4 8 12 16 20 24 
Time (years) 
Nottingham Tenovus Primary Breast Cancer Study 
Lymph Node Stage 
Stage 1 - LN Neg 
Stage 2 - Up to 3 low 
axillary LN +, or internal 
mammary LN + alone 
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Predictive Analysis 
 Immunohistochemistry 
 ER & HER2 
 In Situ Hybridisation 
 HER2 FISH 
Genomic Analysis 
 21 gene OncoTypeDx assay 
 


Immunohistochemistry In Situ Hybridisation 
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Response to Herceptin of HER2+ Cancer 
Cardiff Data: 2005-2008 
Herceptin 
No Herceptin 
Oncotype DX® 21-Gene  
Recurrence Score (RS) Assay 
PROLIFERATION 
Ki-67 
STK15 
Survivin 
Cyclin B1 
MYBL2 
ESTROGEN 
ER 
PR 
Bcl2 
SCUBE2 
INVASION 
Stromelysin 3 
Cathepsin L2 
HER2 
GRB7 
HER2 
BAG1 GSTM1 
REFERENCE 
Beta-actin 
GAPDH 
RPLPO 
GUS 
TFRC 
CD68 
16 Cancer and 5 Reference Genes From 3 Studies 
Category RS (0 -100) 
Low risk RS <18 
Int risk RS 18 - 30 
High risk RS ≥ 31 
Paik et al. N Engl J Med. 2004;351:2817-2826. 
RS = + 0.47 x HER2 Group Score  
-  0.34 x ER Group Score  
+ 1.04 x Proliferation Group Score 
+ 0.10 x Invasion Group Score  
+ 0.05 x CD68 
-  0.08 x GSTM1 
-  0.07 x BAG1 
Oncotype DX® Clinical Validation:  
B-14 Results – Distant Recurrence 
Distant Recurrence for the three distinct cohorts identified  
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Quality Assurance of Diagnostic & Prognostic 
Cancer Biomarking 
  
    Tumour size 
 Histological type 
 Histological grade 
 Lymph node stage 
 Vascular invasion 
 Excision margins 
 In situ component 
 Analysis performed and results  reported by pathologists 
 
  
Quality Assurance of Diagnostic & Prognostic 
Cancer Biomarking: Probable Error Rate 
Susan G. Komen for the Cure White Paper: June 2006 
 
  
   
 While it is exceedingly difficult to determine the incidence of 
incorrect breast cancer diagnoses in the United States, our 
consultants estimate that the error rate could be as high as 2% 
to 4%.  
 If accurate, as many as 5,000 to 10,000 patients diagnosed with 
invasive or in-situ breast cancer each year may have been 
misdiagnosed and inappropriately treated (Appendix II). 
  More than 90,000 people currently living with breast cancer 
may, in fact, be living (or dying) with an incorrect diagnosis 
(Appendix II). 
 
 
 
 
Quality Assurance of Diagnostic & Prognostic 
Cancer Biomarking 
  
    Training in Pathology (Doctors & Biomedical Scientists) 
 Undergraduate 
 Postgraduate  
 General 
 Sub-specialist 
 Continual Professional Development 
 External Quality assurance 
 Audit 
 
 
 
 
 
 
Quality Assurance of Predictive  
Breast Cancer Cancer Analysis 
  
   Hormone Receptor 
HER2 Receptor 
 Performed by biomedical scientists in 
hospital or private pathology laboratories 
 Results interpreted and reported by senior 
biomedical scientists and/or sub-specialist 
pathologists 
 
 
 
 
Unrecognised Error Rate 
  
   Hormone Receptor 
An official inquiry convened in July 2007 
 In Newfoundland and Labrador over 
2,000 originally ER-negative cases were 
retested in another laboratory in Ontario, 
and nearly 40% were found to be ER-
positive   
 
 
 “We all make the assumption that every test is 
done well. It turns out that it’s not a correct 
assumption”  
 Lee Newcomer, a senior cancer doctor 
Wall Street Journal – Jan 4 2008 
 “While far from being scientific, the false-negative 
rate of IHC testing for both receptors in my 
consulting practice over the past 10 years is about 
30%, which is similar to that of other experienced 
consulting pathologists I have spoken with on this 
issue” 
 D. Craig Allred. Commentary: Hormone Receptor Testing 
in Breast Cancer: A Distress Signal from Canada. The 
Oncologist 13: 1134-1136, 2008 
 
An Admission by an Expert  

How Can We Improve Quality of 
Predictive Biomarking of Breast Cancer ? 
Standardization? 
4.8 million ways of doing the same thing….  
314 = 4.8 mio procedures (assuming 3 choices in 14 steps) 
Preparation  
phase 
IHC Staining 
Interpretation  
phase 
Biopsing 
Fixation 
Preparation 
Sectioning 
Drying 
Deparaffination 
Pre-treatment 
Antibody 
Detection 
Counterstain 
Control 
Cut-off value 
Tumor entity 
Reporting 
  
 Pre-analytical 
 Tissue fixation  
 Antigen retrieval 
 Analytical 
 Primary antibody specificity & sensitivity 
 Secondary detection system amplification  
 Post-analytical 
 Interpretation & objective scoring & reporting 
Optimisation of  Methodology 
  
   Challenges to Optimisation of  
Pre-Analytical Factors 
 
 Quality of tissue preservation  
 Variable delay in fixation  
 Variable quality of fixative  
 Variable penetration of fixative  
 Variable duration of fixation  
 Quality of tissue sample 
 Core biopsy vs resection specimen 
 Quality of tissue sections 
 Variable and uneven section thickness 
 Variable drying temperature 
 Variable length of storage 
 
  Recommended Solutions 
 
 Standardisation of Tissue Preservation  
 Avoidance of delay in fixation (<30 min) 
 Use of appropriate fixative  
 4% buffered formalin (pH control) 
 Adequate penetration of fixative  
 Tissue slicing (5-10 mm) 
 Adequate duration of fixation  
 6-48h at room temperature 
 
 Plethora of Analytical Reagents 
 Primary antibodies 
 Secondary Detection Agents & Systems 
 Variety of Antigen Retrieval Methods 
 Types of antigen retrieval reagents 
 High pH, Low pH 
 Modes of antigen retrieval  
 Microwave ovens, pressure cookers, water baths, auto-
stainer platforms 
 
 Challenges to Optimisation of  
Analytical Factors 




Recommended Solutions 
 Use of High Quality Kit Based Reagents 
 Highest specificity primary antibodies 
 Highest sensitivity secondary detection systems 
 Use of Standardised Antigen Retrieval Platforms 
 Reliable consistent quality reproducible antigen retrieval 
 Use of semi-automation (e.g. Dako PT-Link) or full 
automation (e.g. Ventana Benchmark) 
 
 HercepTest and HER2 
FISH pharmDx was used in 
clinical trials for use of 
Herceptin in breast cancer.  
 5+ million tests performed 
worldwide since launch in 
1998 
 HercepTest has also been 
used in gastric cancer 
clinical trial (ToGA) 
Use of clinically validated assay systems 
3+ HercepTest result 
 Challenges to Optimisation of  
Post- Analytical Factors 
 
• Variation in approach to microscopic 
examination 
• Use of different objective lens power 
• ‘hot’ spot vs random vs total tumour area 
analysis 
• Variation in method of scoring 
• H-Score vs Quick Score 
• Variation in thresholds for negative results 
• <1% vs <10%; Allred 0-1 vs 0-2 
 
 
 
Recommended Solutions: I 
• Use of Optimised Protocols 
• Microscopic examination 
• Interpretation 
• Scoring 
• Reporting 
• Evidence based consensus guidelines for 
scoring 
• Clinically validated thresholds for reporting 
positive and negative results 
Frequent Effective Evaluation of the 
Performance via Participation in 
External Quality Assurance Schemes 
Recommended Solutions: II 
Headquarters in 
London 
Participation in External Quality Assurance Scheme:  
UK National External Quality Assurance Scheme (UKNEQAS) 
• >5000 Slides per run 
• 4 Weeks of assessments 
• 1-2 days depending on 
module 
• 4 assessors & 1 driver  
UKNEQAS Tissue Section 
Controls for ER 
Improvement in Performance on External 
Control Samples 
UK NEQAS HER-2 CELL LINES 
jasani@cf.ac.uk 

 UK NEQAS Updated HER-2 Pass Rates:  
Data From UK only (2003- present) 
-  Effective Feedback & monitoring of UK labs. 
 -  UK labs have to pass the NEQAS assessments to be accredited (CPA) 
 HER-2 Assessment Pass Rates:  
Data From 36 countries - UK & Overseas  
 Standardised Kit or Home Brew Method? 
Quality of analyticall performance can be 
improved through:  
 Use of recommended optimised kit based 
reagents and methods 
Regular participation in External Quality 
Assurance Schemes 
 
Conclusion 
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Bharat.jasani@nu.edu.kz 
Oncotype DX® Clinical Validation:  
RS as Continuous Predictor 
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Nottingham Prognostic Index 
NPI =  0.2 x size (cm)  
   + lymph node stage (1, 2, 3)  
   + grade (1, 2, 3) 
Nottingham Primary Breast Cancer Study 
Nottingham Prognostic Index 
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